19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the Colon


Colon | Colon Cancer

What is the purpose of this trial?

This is a clinical research study that is designed to test if the administration of another medicine, called bevacizumab, an antibody that blocks blood vessels growth (angiogenesis) will increase the amount of your prescribed 5-FU that gets into the cancer cells in the liver. The objective is to perform 19F-MRS on patients with colorectal cancer liver metastases in order to determine the concentration of 5FU in liver metastases and AUC for the 48 hour infusion when given with and without bevacizumab. To correlate intratumoral pharmakinetic parameters with plasma 5FU levels and plasma 5FU AUC, and correlation of intratumoral 5FU with time to progression on current regimen Patients will be treated twice only on this study, once using a conventional 5FU based chemotherapy for colorectal cancer and a second time using bevacizumab followed by the same chemotherapy.

Participation Guidelines

18 Years and older

Click here for detailed information about who can participate in this trial.

Yale Cancer Center
Last Updated:
Study HIC#: